Innoviva, Inc. (NASDAQ:INVA) Stock Holdings Lifted by Nomura Holdings Inc.

Nomura Holdings Inc. raised its position in Innoviva, Inc. (NASDAQ:INVAGet Rating) by 27.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,102,018 shares of the biotechnology company’s stock after purchasing an additional 458,966 shares during the quarter. Nomura Holdings Inc.’s holdings in Innoviva were worth $41,510,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Lido Advisors LLC purchased a new position in Innoviva in the first quarter valued at about $366,000. Point72 Hong Kong Ltd purchased a new position in Innoviva in the first quarter valued at about $76,000. Quantamental Technologies LLC purchased a new position in Innoviva in the first quarter valued at about $282,000. Quantbot Technologies LP purchased a new position in Innoviva in the first quarter valued at about $109,000. Finally, Royal Bank of Canada boosted its stake in shares of Innoviva by 259.4% during the 1st quarter. Royal Bank of Canada now owns 35,439 shares of the biotechnology company’s stock worth $686,000 after acquiring an additional 25,579 shares in the last quarter.

Innoviva Price Performance

NASDAQ INVA opened at $12.81 on Wednesday. Innoviva, Inc. has a twelve month low of $12.68 and a twelve month high of $20.71. The company has a debt-to-equity ratio of 0.78, a quick ratio of 3.18 and a current ratio of 3.18. The stock has a market capitalization of $892.93 million, a PE ratio of 9.93 and a beta of 0.48. The stock has a 50-day simple moving average of $14.07 and a 200 day simple moving average of $15.97.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. TheStreet downgraded Innoviva from a “b-” rating to a “c” rating in a research note on Friday, July 29th. StockNews.com downgraded Innoviva from a “buy” rating to a “hold” rating in a research note on Friday, July 29th. Finally, The Goldman Sachs Group assumed coverage on Innoviva in a research note on Wednesday, July 20th. They set a “neutral” rating for the company.

Innoviva Company Profile

(Get Rating)

Innoviva, Inc engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Featured Articles

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva, Inc. (NASDAQ:INVAGet Rating).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.